Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT06066424 |
TitlePhase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Phase
Phase 1
|
Date Added 2023-10-04 |
Location
Texas, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06065371 |
TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Phase
Phase 1
|
Date Added 2023-10-03 |
Location
Michigan, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
capecitabine, Sacituzumab govetican |
Tags
MSS/ MMRp
|
NCT ID NCT06060704 |
TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | Phase
Phase 2
|
Date Added 2023-09-29 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06055439 |
TitleA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Phase
Phase 1, Phase 2
|
Date Added 2023-09-26 |
Location
Georgia, United States
Illinois, United States Pennsylvania, United States Tennessee, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06047015 |
TitleIrreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer | Phase
Phase 1
|
Date Added 2023-09-21 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
NCT ID NCT06043713 |
TitleAutologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Phase
Phase 1
|
Date Added 2023-09-21 |
Location
Washington, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Bendamustine, Cyclophosphamide, Fludarabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06039202 |
TitlePhase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-09-15 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
CA102N, TAS-102 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06039384 |
TitleA Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Phase
Phase 1
|
Date Added 2023-09-15 |
Location
California, United States
Colorado, United States Michigan, United States Texas, United States Virginia, United States Italy Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Adagrasib, INCB099280 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06034860 |
TitleStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Phase
Phase 1
|
Date Added 2023-09-13 |
Location
California, United States
Indiana, United States Missouri, United States New York, United States Virginia, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
MT-8421, Nivolumab, Opdivo |
Tags
MSI-H/ MMRd
|
NCT ID NCT06026774 |
TitleClinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms | Phase
Phase 1
|
Date Added 2023-09-07 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|